경구 약물전달 시스템 시장 - 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Global Buccal Drug Delivery Systems Market size will expand at an 8.6% CAGR from 2024 to 2032, fueled by the increasing prevalence of diabetes and cardiovascular diseases.

Buccal drug delivery systems are being crafted as a non-invasive alternative for medication administration, ensuring improved absorption and quicker action onset. By utilizing the mouth's mucous membranes for drug delivery, these systems boost patient compliance and convenience, especially for those needing frequent doses or struggling with oral tablets. As per WHO, cardiovascular diseases (CVDs) lead to global mortality, accounting for around 17.9 million deaths annually. In this context, buccal drug delivery systems are positioning themselves as a potent solution, promising swift medication absorption and heightened patient compliance for CVD management.

The market is segregated into product type, application, system type, end-use, and region.

In terms of product type, the buccal gels segment in the buccal drug delivery systems industry will grow at a considerable CAGR through 2032. This surge is driven by the rising demand for innovative medication administration methods. Formulated for controlled and sustained drug release via the buccal mucosa, buccal gels aim to boost absorption and therapeutic effectiveness. Ongoing advancements in gel formulations are fine-tuning release profiles and ingredient stability, further amplifying the efficacy of the systems.

By application, the buccal drug delivery systems market share from the neurological disorders segment is projected to rise from 2024 to 2032. This growth is attributed to the rising demand for specialized formulations and technologies. By delivering drugs via the buccal mucosa, these systems ensure rapid absorption and sidestep first-pass metabolism, a critical factor for central nervous system medications. Such an approach not only bolsters the management of neurological conditions but also guarantees improved bioavailability and patient adherence.

Regionally, the Europe buccal drug delivery systems industry size is projected to witness a significant CAGR between 2024 and 2032 due to the growing patient preference for alternative routes of administration. Buccal drug delivery enhances medication adherence by providing faster absorption and minimizing gastrointestinal side effects. Furthermore, regional advancements are focused on crafting more potent formulations and technologies to elevate drug stability and release profiles.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for non-invasive drug delivery methods
    • 3.2.1.2 Advancements in buccal drug delivery technologies
    • 3.2.1.3 Rising prevalence of chronic diseases requiring long-term medication
    • 3.2.1.4 Growing awareness and acceptance of buccal drug delivery systems
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited market acceptance due to patient discomfort
    • 3.2.2.2 High development and production costs
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Future market trends
• 3.6 Regulatory landscape
• 3.7 Technological landscape
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Buccal tablets
• 5.3 Buccal films
• 5.4 Buccal gels
• 5.5 Buccal sprays
• 5.6 Buccal patches

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pain management
• 6.3 Hormone replacement
• 6.4 Cardiovascular diseases
• 6.5 Neurological disorders
• 6.6 Respiratory disorders
• 6.7 Addiction treatment
• 6.8 Mental health disorders

Chapter 7 Market Estimates and Forecast, By System Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Matrix systems
• 7.3 Reservoir systems

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Homecare settings
• 8.4 Specialty clinics
• 8.5 Ambulatory surgical centers
• 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 Collegium Pharmaceutical, Inc.
• 10.4 Endo International plc
• 10.5 Galderma SA
• 10.6 Indivior plc
• 10.7 Johnson and Johnson Services, Inc.
• 10.8 Kyowa Kirin Co., Ltd.
• 10.9 Mallinckrodt plc
• 10.10 Neurelis, Inc.
• 10.11 Novartis AG
• 10.12 Pfizer Inc.
• 10.13 Sanofi
• 10.14 Takeda Pharmaceuticals Company Limited
• 10.15 Teva Pharmaceutical Industries Ltd.